235 related articles for article (PubMed ID: 7734324)
1. Amplification of the MDM2 gene in human breast cancer and its association with MDM2 and p53 protein status.
McCann AH; Kirley A; Carney DN; Corbally N; Magee HM; Keating G; Dervan PA
Br J Cancer; 1995 May; 71(5):981-5. PubMed ID: 7734324
[TBL] [Abstract][Full Text] [Related]
2. Amplification of Mdmx and overexpression of MDM2 contribute to mammary carcinogenesis by substituting for p53 mutations.
Yu Q; Li Y; Mu K; Li Z; Meng Q; Wu X; Wang Y; Li L
Diagn Pathol; 2014 Mar; 9():71. PubMed ID: 24667108
[TBL] [Abstract][Full Text] [Related]
3. mdm2 gene alterations and mdm2 protein expression in breast carcinomas.
Marchetti A; Buttitta F; Girlando S; Dalla Palma P; Pellegrini S; Fina P; Doglioni C; Bevilacqua G; Barbareschi M
J Pathol; 1995 Jan; 175(1):31-8. PubMed ID: 7891224
[TBL] [Abstract][Full Text] [Related]
4. MDM2 gene amplification in human breast cancer.
Quesnel B; Preudhomme C; Fournier J; Fenaux P; Peyrat JP
Eur J Cancer; 1994; 30A(7):982-4. PubMed ID: 7946596
[TBL] [Abstract][Full Text] [Related]
5. Expression of p53 and mdm2 mRNA and protein in colorectal carcinomas.
Broll R; Stark A; Windhövel U; Best R; Strik MW; Schimmelpenning H; Schwandner O; Kujath P; Bruch HP; Duchrow M
Eur J Cancer; 1999 Jul; 35(7):1083-8. PubMed ID: 10533452
[TBL] [Abstract][Full Text] [Related]
6. Mdm2 gene amplification in gastric cancer correlation with expression of Mdm2 protein and p53 alterations.
Günther T; Schneider-Stock R; Häckel C; Kasper HU; Pross M; Hackelsberger A; Lippert H; Roessner A
Mod Pathol; 2000 Jun; 13(6):621-6. PubMed ID: 10874665
[TBL] [Abstract][Full Text] [Related]
7. The p53-MDM2 interaction in a cancer-prone family, and the identification of a novel therapeutic target.
Picksley SM; Spicer JF; Barnes DM; Lane DP
Acta Oncol; 1996; 35(4):429-34. PubMed ID: 8695156
[TBL] [Abstract][Full Text] [Related]
8. [Study of mdm2 gene amplification in primary breast tumors].
Fontana X; Ferrari P; Abbes M; Monticelli J; Namer M; Bussière F
Bull Cancer; 1994 Jul; 81(7):587-92. PubMed ID: 7742600
[TBL] [Abstract][Full Text] [Related]
9. p53 protein expression in breast carcinomas. Comparative study with the wild type p53 induced proteins mdm2 and p21/waf1.
Giannikaki E; Kouvidou C; Tzardi M; Stefanaki K; Koutsoubi K; Gregoriou M; Zois E; Kakolyris S; Mavroudi C; Delides G; Georgoulias V; Kanavaros P
Anticancer Res; 1997; 17(3C):2123-7. PubMed ID: 9216675
[TBL] [Abstract][Full Text] [Related]
10. MDM2 gene amplification and expression in non-small-cell lung cancer: immunohistochemical expression of its protein is a favourable prognostic marker in patients without p53 protein accumulation.
Higashiyama M; Doi O; Kodama K; Yokouchi H; Kasugai T; Ishiguro S; Takami K; Nakayama T; Nishisho I
Br J Cancer; 1997; 75(9):1302-8. PubMed ID: 9155050
[TBL] [Abstract][Full Text] [Related]
11. p53 gene mutations and expression of p53 and mdm2 proteins in invasive breast carcinoma. A comparative analysis with clinico-pathological factors.
Günther T; Schneider-Stock R; Rys J; Niezabitowski A; Roessner A
J Cancer Res Clin Oncol; 1997; 123(7):388-94. PubMed ID: 9260591
[TBL] [Abstract][Full Text] [Related]
12. Alternative and aberrant messenger RNA splicing of the mdm2 oncogene in invasive breast cancer.
Lukas J; Gao DQ; Keshmeshian M; Wen WH; Tsao-Wei D; Rosenberg S; Press MF
Cancer Res; 2001 Apr; 61(7):3212-9. PubMed ID: 11306511
[TBL] [Abstract][Full Text] [Related]
13. DNA amplifications at 20q13 and MDM2 define distinct subsets of evolved breast and ovarian tumours.
Courjal F; Cuny M; Rodriguez C; Louason G; Speiser P; Katsaros D; Tanner MM; Zeillinger R; Theillet C
Br J Cancer; 1996 Dec; 74(12):1984-9. PubMed ID: 8980401
[TBL] [Abstract][Full Text] [Related]
14. p53 and MDM2 alterations in osteosarcomas: correlation with clinicopathologic features and proliferative rate.
Lonardo F; Ueda T; Huvos AG; Healey J; Ladanyi M
Cancer; 1997 Apr; 79(8):1541-7. PubMed ID: 9118036
[TBL] [Abstract][Full Text] [Related]
15. RT-PCR amplification of RNA extracted from formalin-fixed, paraffin-embedded oral cancer sections: analysis of p53 pathway.
Tachibana M; Shinagawa Y; Kawamata H; Omotehara F; Horiuchi H; Ohkura Y; Kubota K; Imai Y; Fujibayashi T; Fujimori T
Anticancer Res; 2003; 23(3C):2891-6. PubMed ID: 12926130
[TBL] [Abstract][Full Text] [Related]
16. Clinical relevance of immunohistochemical expression of p53-targeted gene products mdm-2, p21 and bcl-2 in breast carcinoma.
Bánkfalvi A; Tory K; Kemper M; Breukelmann D; Cubick C; Poremba C; Füzesi L; Lellè RJ; Böcker W
Pathol Res Pract; 2000; 196(7):489-501. PubMed ID: 10926327
[TBL] [Abstract][Full Text] [Related]
17. In squamous cell carcinoma of the vulva, overexpression of p53 is a late event and neither p53 nor mdm2 expression is a useful marker to predict lymph node metastases.
Emanuels AG; Koudstaal J; Burger MP; Hollema H
Br J Cancer; 1999 Apr; 80(1-2):38-43. PubMed ID: 10389975
[TBL] [Abstract][Full Text] [Related]
18. Centrosome hyperamplification in human cancer: chromosome instability induced by p53 mutation and/or Mdm2 overexpression.
Carroll PE; Okuda M; Horn HF; Biddinger P; Stambrook PJ; Gleich LL; Li YQ; Tarapore P; Fukasawa K
Oncogene; 1999 Mar; 18(11):1935-44. PubMed ID: 10208415
[TBL] [Abstract][Full Text] [Related]
19. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
[TBL] [Abstract][Full Text] [Related]
20. MDM-2 oncoprotein overexpression in laryngeal squamous cell carcinoma: association with wild-type p53 accumulation.
Pruneri G; Pignataro L; Carboni N; Luminari S; Capaccio P; Neri A; Buffa R
Mod Pathol; 1997 Aug; 10(8):785-92. PubMed ID: 9267820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]